daraxonrasib
AssetAlso Rasonque, RASONQUETM
RAS(ON) multi-selective inhibitor
- Stage
- Phase 3
- Modality
- Other
- Target
- KRAS
- 3
- Indications
- 0
- Trials
- 2
- Developers
Indications
3Metastatic RAS G12D pancreatic adenocarcinoma
Phase 3, globenewswire.com, 5 Oct 2026
Metastatic RAS G12D pancreatic cancer
Phase 3, globenewswire.com, 5 Oct 2026
Pancreatic cancer
Human trials, endpoints.news, 9 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners2
- Evidence for its targets3
- Competitors2
Every asset’s record: target, stage, trials and the evidence behind it.